Regulation Update · California · Published April 30, 2026
On April 21, 2026, the San Mateo County Board of Supervisors voted unanimously to ban all kratom and 7-hydroxymitragynine (7-OH) products countywide. With the passage of Chapter 4.128, San Mateo became the first Bay Area county to enact a blanket prohibition on kratom — following a small handful of California cities like San Diego, Oceanside, and Newport Beach.
The ordinance takes effect May 21, 2026. That gives Bay Area kratom consumers, retailers, and advocates exactly 30 days to make their case before enforcement begins.
We've spent the past week reading the ordinance, the public comment record, and the peer-reviewed research the Board cited (and the research it didn't). Here's what we found.
What Chapter 4.128 Actually Does
The ordinance is broad. It prohibits the sale, distribution, possession with intent to sell, and manufacture of kratom and any product containing mitragynine or 7-hydroxymitragynine within San Mateo County. That includes:
- Pressed tablets and chewables
- Kratom leaf powder and extracts
- 7-OH-isolate and synthetic 7-OH products
- Liquid shots, capsules, and tinctures
Personal possession for personal use isn't explicitly criminalized at the consumer level — the ordinance targets retailers and distributors. Violations carry administrative fines starting at $500 per offense, escalating to $1,000 and $2,500 for repeat violations within 12 months.
The ordinance also requires existing retailers to remove all kratom inventory from shelves and product feeds by the May 21 enforcement date. Online sales shipping to San Mateo County addresses are also prohibited — which is why responsible online retailers (Favor'd Alkz included) are updating their ZIP-code blocklists ahead of enforcement.
The Concerns the Board Raised — And Why They Aren't Wrong (At First Glance)
It's important to take the Board's stated concerns seriously, because some of them are legitimate. The public health staff report cited four primary issues:
Concern #1: Adulterated products
Some kratom products on the market — particularly cheap convenience-store extracts — have been found to contain heavy metals, undisclosed synthetic adulterants, or wildly inconsistent alkaloid concentrations. This is real. The FDA has issued import alerts and seizures over exactly these issues.
Concern #2: ER visits and adverse events
Poison-center calls and ER visits associated with kratom have risen with overall product availability. Again, real data — though the Board's report didn't separate kratom-only cases from polysubstance cases (more on this below).
Concern #3: Lack of standardization
Without federal regulation, dosing, labeling, and product purity vary wildly between brands. A consumer cannot reliably know what they're getting from one product to the next. True.
Concern #4: Youth access
Many California convenience stores sell kratom without age verification. Underage access is a legitimate concern for any psychoactive product.
These four issues are not invented. They are real, documented problems in the unregulated kratom marketplace. The question is whether prohibition — the policy lever the Board chose — actually solves them. The peer-reviewed evidence says it does not.
What the Peer-Reviewed Science Actually Shows
Here's where the Board's reasoning breaks down. The staff report citations leaned heavily on FDA import alerts, DEA's withdrawn 2016 scheduling attempt, and aggregated poison-center data — while the underlying clinical and epidemiological literature on kratom paints a more nuanced picture. Six studies in particular are worth knowing:
Study 1 · Johns Hopkins, 2020
"Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic"
Garcia-Romeu A et al. · Drug & Alcohol Dependence · PMID: 32029298
A survey of 2,798 active kratom users found the population is overwhelmingly adult, employed, and using kratom to reduce or replace opioid use. Most users reported low risk of dependence and few serious adverse events. The authors concluded kratom presents a low-risk profile when used orally by adults at typical doses — a finding directly at odds with prohibition-justifying narratives.
Study 2 · University of Rochester, 2017
"Patterns of use and self-reported effects of Kratom (Mitragyna speciosa) use among regular users"
Swogger MT et al. · Drug & Alcohol Dependence · PMID: 27864175
An online survey of regular kratom users (n=8,049) reported a low incidence of severe adverse effects. The most common side effects were mild gastrointestinal complaints, not the catastrophic outcomes invoked by prohibition advocates.
Study 3 · University of Florida, 2020
"Opioid use disorder treatment with kratom: Provider attitudes and clinical considerations"
Smith KE et al. · Journal of Substance Abuse Treatment · PMID: 31808742
Clinical providers reported observing patients who self-managed opioid withdrawal with kratom. The paper found that for many patients, kratom served as a step-down tool away from prescription and illicit opioids — the exact opposite of the "kratom causes opioid harm" framing.
Study 4 · LSU Health, 2020
"Kratom-Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review"
Eastlack SC, Cornett EM, Kaye AD · Pain Therapy · PMID: 31994019
A comprehensive pharmacology review concluded kratom shows therapeutic potential for pain and opioid use disorder, with adverse effects that are generally mild and dose-dependent when products are uncontaminated.
Study 5 · University of Florida, 2022
"Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa)"
Hartley C et al. · Journal of Clinical Pharmacology · PMID: 34775626
A clinical pharmacology review confirmed kratom's atypical opioid receptor activity profile (partial mu-opioid agonism, kappa antagonism) results in a markedly different risk profile than full-agonist opioids — supporting the case for differentiated regulation rather than blanket prohibition.
Study 6 · UF / Florida Department of Health, 2022
"Health Effects Associated With Kratom (Mitragyna speciosa) and Polysubstance Use: A Narrative Review"
Striley CW et al. · Substance Abuse · PMID: 35645563
A critical review of kratom-attributed adverse events found that the majority involved polysubstance use, contamination, or extreme dosing — not standard adult use of pure kratom. The authors specifically warned against conflating polysubstance harm with kratom harm in policy decisions — precisely the conflation the San Mateo Board made.
The Adulteration Paradox
Here's where the Board's logic gets self-defeating: the ER visits and adverse events the Board cited are overwhelmingly tied to adulterated, contaminated, or polysubstance kratom — the kind sold in unregulated convenience-store shelves with no third-party testing.
A countywide ban does not eliminate that supply — it pushes consumers to more unregulated sources: out-of-county trips, unverified online sellers, the gray market, mailed gifts. Consumers who were already buying tested, COA-published products from responsible retailers either:
- Stop using kratom (and may return to opioids or alcohol they were stepping down from), or
- Source it from less reliable channels — precisely the channels that produced the adulterated-product harms in the first place
Prohibition does not improve product safety. It eliminates the regulated, transparent suppliers and leaves the unregulated suppliers untouched. This is the well-documented failure mode of every prohibition policy in modern public health history — from alcohol in the 1920s to cannabis in the 2000s. The harm-reduction literature is clear on this point.
The KCPA Alternative the Board Didn't Consider
There's an existing model that addresses every legitimate concern the Board raised — without resorting to prohibition. It's called the Kratom Consumer Protection Act (KCPA), and as of April 2026, 18 U.S. states have enacted some form of it.
A typical KCPA framework includes:
- Age verification — sales restricted to adults 21 and older (addresses youth access concern)
- Mandatory third-party lab testing — every batch tested for alkaloid content, heavy metals, microbials, residual solvents (addresses adulteration concern)
- Labeling requirements — mg per serving, total alkaloid content, batch/lot number, COA accessibility (addresses standardization concern)
- Synthetic-adulterant prohibition — no kratom products with added synthetic 7-OH, mitragynine analogs, or other psychoactive compounds (addresses ER-visit concern)
- Retailer licensing — sellers register with the state, subject to inspection, lose license for violations (addresses enforcement concern)
States with active KCPA frameworks include Florida, Arizona, Colorado, Georgia, Kentucky, Maryland, Nevada, Oregon, Texas, Virginia, and a growing list of others. None of these states have seen the cataclysmic public health outcomes prohibition advocates predicted. Most have seen the opposite: a more transparent kratom marketplace, fewer adulterated products, and consumer access to tested products that displace the unregulated supply.
A countywide KCPA-style ordinance would have addressed every concern in the San Mateo Board's staff report. The Board chose prohibition instead.
Where Favor'd Alkz Stands
We are a small, transparency-first kratom company. We don't have a stake in convenience-store shelf space or import-shipping shortcuts. Every product we sell goes through:
- ISO/IEC 17025-accredited third-party laboratory testing on every batch — alkaloid content, residual solvents (Class I, II, III), heavy metals via ICP-MS, microbial contamination
- Published Certificates of Analysis for every lot number — downloadable directly from our product pages
- Direct-to-consumer fulfillment — no retail middleman, no chain-of-custody handoffs, no opportunity for adulteration after we ship
- Age verification at checkout
- Real-time ZIP-code compliance — orders to prohibited jurisdictions are blocked at checkout, including all jurisdictions with active local bans (and San Mateo County, effective May 21)
We are not arguing against any regulation of kratom. We are arguing for the right kind: science-based, harm-reductive, transparency-mandating regulation that improves product safety rather than eliminating safe products. The KCPA framework exists. It works. It's the answer to every legitimate concern the San Mateo Board raised. It deserves consideration before May 21.
Take Action: Contact Your San Mateo County Supervisor
If you live, work, or do business in San Mateo County, your supervisor needs to hear from you before May 21. The ordinance was passed; an amendment, exemption, or KCPA-aligned replacement is still possible during the 30-day enforcement window. The most effective contact is a phone call directly to your district supervisor's office.
Find your district at the official county website — smcgov.org/bos — then call your supervisor directly.
Board of Supervisors · Direct Lines
District 1 — Jackie Speier
Phone: (650) 363-4571
Email: SMCSupSpeier@smcgov.org
District 2 — Noelia Corzo
San Mateo, Foster City, Belmont (north of Ralston)
Phone: (650) 363-4568
Email: ncorzo@smcgov.org
District 3 — Ray Mueller
Coastside, Atherton, Menlo Park, Portola Valley, Woodside
Phone: (650) 363-4569
Email: SMC_SupMueller@smcgov.org
District 4 — Lisa Gauthier
East Palo Alto, Redwood City, North Fair Oaks
Phone: (650) 363-4570
Email: SMC_SupGauthier@smcgov.org
District 5 — David Canepa
Daly City, Brisbane, Colma, South San Francisco, San Bruno, Pacifica
Phone: (650) 363-4572
Email: dcanepa@smcgov.org
Board of Supervisors office: 500 County Center, Redwood City, CA 94063. Public comment may also be submitted via email, written letter, or in person at regular Board meetings (smcgov.org/bos).
A Concrete Script You Can Use
Office staff log calls. A 60-second polite call from a constituent matters more than most people realize. Here's a script:
If you'd rather email, send to the supervisor's official address (linked from smcgov.org/bos) and copy the Board Clerk for the public record.
Whatever you do, do it before May 21. After that date, the ordinance is enforced and amendments require a separate Board vote on a separate agenda — a much higher bar.
Further Reading
- FA Kratom Regulation Map — live state-by-state status, including local ordinances
- Favor'd Alkz Lab Results — ISO/IEC 17025 COAs for every batch we ship
- American Kratom Association — State Laws & KCPA Tracker
- KCPA Model Legislation
- San Mateo County Board of Supervisors — agendas, minutes, contact info
FDA Disclaimer
These statements have not been evaluated by the Food and Drug Administration. Information in this article is provided for educational and advocacy purposes only and is not intended as medical advice. 7-hydroxymitragynine and kratom products are not intended to diagnose, treat, cure, or prevent any disease. Favor'd Alkz does not ship kratom products to jurisdictions where they are prohibited by law. Verify your local ordinance before ordering. Citations link to peer-reviewed publications indexed in PubMed; readers are encouraged to review the underlying studies independently.



